Marinomed Biotech AG
MARI.VI · VIE
6/30/2025 | 3/31/2025 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | -0.05 |
| FCF Yield | 0.00% | 0.00% | -4.95% | -2.81% |
| EV / EBITDA | 0.00 | 0.00 | -38.98 | -41.14 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | -15.33% | -18.49% |
| Gross Margin | 0.00% | 0.00% | 39.89% | -204.38% |
| Cash Conversion Ratio | – | – | 0.32 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | -5.37% | -21.59% | -17.65% | -7.57% |
| Free Cash Flow Growth | 0.00% | 0.00% | -0.06% | -145.44% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | -23.23 | -15.29 |
| Interest Coverage | 0.00 | 0.00 | -0.19 | -2.83 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 1.28 | 2.12 |
| Cash Conversion Cycle | 0.00 | 0.00 | 148.11 | 253.77 |